pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
6d
Webinar: Optimizing Cell Therapy Manufacturing Efficiency with Cryopreserved Cells
biospace
6d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
6d
STAT+: Scientists debut map of basal ganglia, a key brain region involved in an array of diseases
stat
6d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
6d
Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-cel
fiercebiotech
7d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
7d
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
endpoints
7d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
7d
A new tactic in the war over out-of-network bills: Health care providers are suing employers
stat
7d
STAT+: Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
stat
8d
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
biopharma dive
8d
Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
endpoints
8d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
8d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
8d
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
stat
8d
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
fiercebiotech
8d
STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds
stat
8d
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
stat
9d
STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
stat
9d
STAT+: Trump administration removes WuXi AppTec from its Chinese military list
stat
9d
STAT+: Hospitals win the midterms, and Chopping Very Strategically
stat
9d
STAT+: Heart association meeting’s readout is trending ‘neutral’
stat
9d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
9d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
9d
STAT+: Gene therapy’s long-debated cancer risk materializes
stat
9d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
9d
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
stat
10d
FDA’s new rare disease framework aims to leverage patient voices for better innovation
biospace
10d
Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier
biospace
10d
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
stat
← prev
page 2 of 18
next →